Kim Blickenstaff Net Worth

The estimated Net Worth of Kim D Blickenstaff is at least $124 Million dollars as of 23 May 2024. Mr. Blickenstaff owns over 4,434 units of Tandem Diabetes Care Inc stock worth over $762,645 and over the last 20 years he sold TNDM stock worth over $112,362,609. In addition, he makes $10,545,000 as Chairman of the Board at Tandem Diabetes Care Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Blickenstaff TNDM stock SEC Form 4 insiders trading

Kim has made over 34 trades of the Tandem Diabetes Care Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 4,434 units of TNDM stock worth $229,371 on 23 May 2024.

The largest trade he's ever made was buying 1,600,000 units of Tandem Diabetes Care Inc stock on 23 March 2017 worth over $2,000,000. On average, Kim trades about 92,573 units every 123 days since 2005. As of 23 May 2024 he still owns at least 17,848 units of Tandem Diabetes Care Inc stock.

You can see the complete history of Mr. Blickenstaff stock trades at the bottom of the page.

Kim Blickenstaff biography

Kim D. Blickenstaff serves as Chairman of the Board of the Company. Mr. Blickenstaff has served as the Chairman of our board of directors since March 2020. Mr. Blickenstaff previously served as Executive Chairman of our board of directors since March 2019, and on our board of directors since September 2007. Mr. Blickenstaff also previously served as our President and Chief Executive Officer from September 2007 to March 2019. Prior to joining us, Mr. Blickenstaff served as Chairman and Chief Executive Officer of Biosite Incorporated, or Biosite, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff previously served as a director of Medivation, Inc., a biotechnology company, from 2005 to 2016, until its acquisition by Pfizer, and as a director of DexCom, Inc. (NASDAQ: DXCM), a provider of continuous glucose monitoring systems, from June 2001 to September 2007. Mr. Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He holds a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.

What is the salary of Kim Blickenstaff?

As the Chairman of the Board of Tandem Diabetes Care Inc, the total compensation of Kim Blickenstaff at Tandem Diabetes Care Inc is $10,545,000. There are 1 executives at Tandem Diabetes Care Inc getting paid more, with John Sheridan having the highest compensation of $10,560,900.

How old is Kim Blickenstaff?

Kim Blickenstaff is 67, he's been the Chairman of the Board of Tandem Diabetes Care Inc since 2020. There are 1 older and 21 younger executives at Tandem Diabetes Care Inc. The oldest executive at Tandem Diabetes Care Inc is Dick Allen, 75, who is the Lead Independent Director.

What's Kim Blickenstaff's mailing address?

Kim's mailing address filed with the SEC is 12400, High Bluff Drive, San Diego, San Diego County, California, 92130, United States.

Insiders trading at Tandem Diabetes Care Inc

Over the last 11 years, insiders at Tandem Diabetes Care Inc have traded over $154,253,951 worth of Tandem Diabetes Care Inc stock and bought 4,118,443 units worth $11,618,906 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Douglas A Roeder und Nicole Vitullo. On average, Tandem Diabetes Care Inc executives and independent directors trade stock every 9 days with the average trade being worth of $885,878. The most recent stock trade was executed by Shannon Marie Hansen on 15 August 2024, trading 1,968 units of TNDM stock currently worth $84,093.

What does Tandem Diabetes Care Inc do?

tandem diabetes care, inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. the company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. tandem manufactures and sells the t:slim x2™ insulin pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® insulin pump, the first pump designed for people with greater insulin requirements. tandem is based in san diego, california. safety information please note that this account is not intended to be used for product support or medical advice. if you are having a medical emergency, please dial 911. if you are having an issue with one of our products and need immediate assistance, please call our 24 hour customer support team at 877-801-6901 and press 1 twice. tandem insulin pumps are intended for the subcutan

Complete history of Mr. Blickenstaff stock trades at Dexcom Inc und Tandem Diabetes Care Inc

Tandem Diabetes Care Inc executives and stock owners

Tandem Diabetes Care Inc executives and other stock owners filed with the SEC include:

• John Sheridan,
  President, Chief Executive Officer, Director
• Kim Blickenstaff,
  Chairman of the Board
• Brian Hansen,
  Chief Commercial Officer, Executive Vice President
• Leigh Vosseller,
  Chief Financial Officer, Executive Vice President, Treasurer
• David Berger,
  Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
• Susan Morrison,
  Executive Vice President, Chief Administrative Officer
• Rebecca Robertson,
  Independent Director
• John F. Sheridan,
  Pres, CEO & Director
• David B. Berger Esq.,
  Exec. VP & COO
• Elizabeth Anne Gasser,
  Exec. VP & Chief Strategy Officer
• Brian B. Hansen,
  Exec. VP & Chief Commercial Officer
• Leigh A. Vosseller,
  Exec. VP, CFO & Treasurer
• David B. Berger,
  Exec. VP, Chief Bus. Operations & Compliance Officer and Corp. Sec.
• Susan M. Morrison,
  Exec. VP & Chief Admin. Officer
• Dick Allen,
  Lead Independent Director
• Christopher Twomey,
  Independent Director
• Douglas Roeder,
  Independent Director
• Edward Cahill,
  Independent Director
• Peyton Howell,
  Independent Director
• Kathleen McGroddy-Goetz,
  Independent Director
• Elizabeth Gasser,
  Executive Vice President - Strategy and Corporate Development
• Shannon M. Hansen,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Manuel Jaime,
  Sr. VP of Technology & Digital Health
• Tom Fox,
  Sr. VP of HR & Organizational Devel.
• Ross Sylvia,
  VP of Marketing
• Rick Carpenter,
  Chief Technical Officer
• Jim Leal,
  Sr. VP of Operations
• Richard P. Valencia,
  Director
• Jesse I Treu,
  Director
• Howard E Jr Greene,
  Director
• Fred E Cohen,
  Director
• Lonnie M Smith,
  Director
• Henry Anhalt,
  Director
• John Cajigas,
  CHIEF FINANCIAL OFFICER
• Management Partners Viii, L...,
  
• Venture Partners Ii, L.P.Hl...,
  
• Group Holdings (Sbs) Adviso...,
  
• Parters Vii L P Domain,
  10% owner
• Nicole Vitullo,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• Brian K Halak,
  10% owner
• Robert Anacone,
  EXECUTIVE VP AND CCO
• Brian H Dovey,
  10% owner
• James C Blair,
  10% owner
• Vii Associates Lp Dp,
  10% owner
• Jean Claude Kyrillos,
  EVP & Chief Operating Officer
• Rajwant Sodhi,
  Director
• James Leal,
  Chief Manufacturing Officer
• Shannon Marie Hansen,
  EVP & Chief Legal Officer
• Myoungil Cha,
  Director
• Joao Paulo Falcao Malagueira,
  Director
• Mark David Novara,
  EVP & CHIEF COMMERCIAL OFFICER
• Rick Carpenter,
  Chief Technology Officer